Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever
dc.authorid | 0000-0001-5902-8831 | en_US |
dc.contributor.author | Çetin, Pınar | |
dc.contributor.author | Sarı, İsmail | |
dc.contributor.author | Sözeri, Betül | |
dc.contributor.author | Cam, Özlem | |
dc.contributor.author | Birlik, Merih | |
dc.contributor.author | Akkoç, Nurullah | |
dc.contributor.author | Önen, Fatoş | |
dc.contributor.author | Akar, Servet | |
dc.date.accessioned | 2024-07-12T21:04:07Z | |
dc.date.available | 2024-07-12T21:04:07Z | |
dc.date.issued | 2014 | en_US |
dc.department | Fakülteler, Tıp Fakültesi | en_US |
dc.description.abstract | —Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1–4) and 12 (4– 50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p<0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF. | en_US |
dc.identifier.citation | Çetin, P., Sarı, İ., Sözeri, B., Cam, Ö. vd. (2014). Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever. Inflammation, Springerlink. 38, s. 27-31. | en_US |
dc.identifier.endpage | 31 | en_US |
dc.identifier.issn | 1573-2576 | |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 27 | en_US |
dc.identifier.uri | https://link.springer.com/article/10.1007/s10753-014-0004-1 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12415/3756 | |
dc.identifier.volume | 38 | en_US |
dc.institutionauthor | Cam, Özlem | |
dc.language.iso | en | en_US |
dc.publisher | Springerlink | en_US |
dc.relation.ispartof | Inflammation | en_US |
dc.relation.isversionof | 10.1007/s10753-014-0004-1 | en_US |
dc.relation.publicationcategory | Uluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.snmz | KY01257 | |
dc.subject | familial Mediterranean fever | en_US |
dc.subject | colchicine | en_US |
dc.subject | anakinra | en_US |
dc.subject | canakinumab | en_US |
dc.subject | rilonacept | en_US |
dc.subject | interleukin-1 receptor antagonist protein | en_US |
dc.subject | amyloidosis | en_US |
dc.title | Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean fever | en_US |
dc.type | Article | |
dspace.entity.type | Publication |